| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| M Elsabagh, Y Inabu, T Obitsu, T Sugin. Response of plasma glucagon-like peptide-2 to feeding pattern and intraruminal administration of volatile fatty acids in sheep. Domestic animal endocrinology. vol 60. 2018-03-20. PMID:28431319. |
plasma glp-2 was poorly correlated with glp-1 but positively correlated with insulin, glucose, and bhba. |
2018-03-20 |
2023-08-13 |
Not clear |
| Amalia Gastaldelli, Melania Gaggini, Ralph DeFronz. Glucose kinetics: an update and novel insights into its regulation by glucagon and GLP-1. Current opinion in clinical nutrition and metabolic care. vol 20. issue 4. 2018-03-09. PMID:28463898. |
glucose kinetics are tightly regulated by pancreatic hormones insulin and glucagon, but other hormones, including glucagon-like peptide-1 (glp-1), also play an important role. |
2018-03-09 |
2023-08-13 |
Not clear |
| Sheila A Doggrel. Sgemaglutide in type 2 diabetes - is it the best glucagon-like peptide 1 receptor agonist (GLP-1R agonist)? Expert opinion on drug metabolism & toxicology. vol 14. issue 3. 2018-03-09. PMID:29439603. |
glucagon-like peptide-1 (glp-1) is produced by the gut, and in a glucose-dependent manner stimulates insulin secretion while inhibiting glucagon secretion, reduces appetite and energy intake, and delays gastric emptying. |
2018-03-09 |
2023-08-13 |
human |
| Sheng-Xiao Zhang, Hong-Yan Cai, Xiao-Wen Ma, Li Yuan, Jun Zhang, Zhao-Jun Wang, Yu-Feng Li, Jin-Shun Q. GLP-1 analogue CJC-1131 prevents amyloid β protein-induced impirments of spatial memory and synaptic plasticity in rats. Behavioural brain research. vol 326. 2018-03-07. PMID:28315374. |
glucagon-like peptide 1 (glp-1), a natural gut hormone, was found to be effective in modulating insulin signaling and neural protection, but short half-life limited its clinical application in ad treatment. |
2018-03-07 |
2023-08-13 |
rat |
| Kira Harris, Kimberly Lovin Neal. The Clinical Use of a Fixed-Dose Combination of Insulin Degludec and Liraglutide (Xultophy 100/3.6) for the Treatment of Type 2 Diabetes. The Annals of pharmacotherapy. vol 52. issue 1. 2018-03-06. PMID:28799414. |
to review the pharmacology, pharmacokinetics, efficacy, and safety of the fixed-dose combination of insulin degludec and the glucagon-like peptide-i receptor agonist (glp-1 ra), liraglutide (ideglira) in the treatment of type 2 diabetes mellitus (t2dm). |
2018-03-06 |
2023-08-13 |
Not clear |
| Lindsay Joy Spielman, Deanna Lynn Gibson, Andis Klegeri. Incretin hormones regulate microglia oxidative stress, survival and expression of trophic factors. European journal of cell biology. vol 96. issue 3. 2018-03-02. PMID:28336086. |
both glp-1 and gip stimulate the production and release of insulin from pancreatic β cells as well as exhibit several growth-regulating effects on peripheral tissues. |
2018-03-02 |
2023-08-13 |
human |
| Ehsan Parvaresh Rizi, Tze Ping Loh, Sonia Baig, Vanna Chhay, Shiqi Huang, Jonathan Caleb Quek, E Shyong Tai, Sue-Anne Toh, Chin Meng Kho. A high carbohydrate, but not fat or protein meal attenuates postprandial ghrelin, PYY and GLP-1 responses in Chinese men. PloS one. vol 13. issue 1. 2018-03-02. PMID:29385178. |
we measured fasting and postprandial plasma concentration of glucose, insulin, active glucagon-like peptide-1 (glp-1), total peptide-yy (pyy), and acyl-ghrelin in response to hp, hf, or hc meals. |
2018-03-02 |
2023-08-13 |
human |
| Juan Zheng, Kang-Li Xiao, Lulu Chen, Chaodong Wu, Xiang Hu, Tianshu Zeng, Xiao-Qian Chen, Wen-Juan Li, Xiuling Deng, Huiqing Li, Yu-Ming L. Insulin sensitizers improve the GLP-1 secretion and the amount of intestinal L cells on high-fat-diet-induced catch-up growth. Nutrition (Burbank, Los Angeles County, Calif.). vol 39-40. 2018-02-28. PMID:28606576. |
insulin sensitizers improve the glp-1 secretion and the amount of intestinal l cells on high-fat-diet-induced catch-up growth. |
2018-02-28 |
2023-08-13 |
rat |
| Juan Zheng, Kang-Li Xiao, Lulu Chen, Chaodong Wu, Xiang Hu, Tianshu Zeng, Xiao-Qian Chen, Wen-Juan Li, Xiuling Deng, Huiqing Li, Yu-Ming L. Insulin sensitizers improve the GLP-1 secretion and the amount of intestinal L cells on high-fat-diet-induced catch-up growth. Nutrition (Burbank, Los Angeles County, Calif.). vol 39-40. 2018-02-28. PMID:28606576. |
the aim of this study was to investigate whether insulin resistance can result in impaired glucagon-like peptide (glp)-1 secretion and to determine whether insulin-sensitizing drugs could improve the secretion of glp-1 in catch-up growth rats. |
2018-02-28 |
2023-08-13 |
rat |
| Guillaume Grenet, Audrey Lajoinie, Shams Ribault, Gia Bao Nguyen, Thomas Linet, Augustin Metge, Catherine Cornu, Michel Cucherat, Philippe Moulin, François Gueyffie. Protocol of GLUcose COntrol Safety and Efficacy in type 2 DIabetes, a NETwork meta-analysis: GLUCOSE DINET protocol-Rational and design. Fundamental & clinical pharmacology. vol 31. issue 3. 2018-02-27. PMID:28036112. |
each drug will be analyzed according to its therapeutic class: biguanide, alpha-glucosidase inhibitors, sulfonylureas, glitazones, glinides, insulin, dpp-4 inhibitors, glp-1 analogs, and gliflozins. |
2018-02-27 |
2023-08-13 |
Not clear |
| Ruba Ismail, Ildikó Csók. Novel strategies in the oral delivery of antidiabetic peptide drugs - Insulin, GLP 1 and its analogs. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V. vol 115. 2018-02-21. PMID:28336368. |
up to now, a large number of therapeutic peptides have been produced to treat diabetes including insulin, glucagon-like peptide-1 (glp-1) and its analogs. |
2018-02-21 |
2023-08-13 |
Not clear |
| T C Haufe, A D Gilley, K M Goodrich, C M Ryan, A T Smithson, M W Hulver, D Liu, A P Neilso. Grape powder attenuates the negative effects of GLP-1 receptor antagonism by exendin-3 (9-39) in a normoglycemic mouse model. Food & function. vol 7. issue 6. 2018-02-20. PMID:27189193. |
glp-1 is a feeding hormone that increases insulin secretion after carbohydrate consumption, and increased glp-1 secretion may be responsible for some of the beneficial effects on glycemic control after flavanol consumption. |
2018-02-20 |
2023-08-13 |
mouse |
| Estelle Grasset, Anthony Puel, Julie Charpentier, Xavier Collet, Jeffrey E Christensen, François Tercé, Rémy Burceli. A Specific Gut Microbiota Dysbiosis of Type 2 Diabetic Mice Induces GLP-1 Resistance through an Enteric NO-Dependent and Gut-Brain Axis Mechanism. Cell metabolism. vol 25. issue 5. 2018-02-19. PMID:28467926. |
altogether, insulin secretion and gastric emptying require functional glp-1 receptor and neuronal nitric oxide synthase in the enteric nervous system within a eubiotic gut microbiota environment. |
2018-02-19 |
2023-08-13 |
mouse |
| Noushafarin Khajavi, Heike Biebermann, Matthias Tschöp, Richard DiMarch. Treatment of Diabetes and Obesity by Rationally Designed Peptide Agonists Functioning at Multiple Metabolic Receptors. Endocrine development. vol 32. 2018-02-14. PMID:28873389. |
these mixed peptide agonists are designed to pharmacologically integrate the insulinotropic and anorexigenic effects of glp-1, the thermogenic and lipolytic activities of glucagon, and the insulinotropic and insulin sensitizing properties of gip. |
2018-02-14 |
2023-08-13 |
Not clear |
| Rajesh Gar. NUTRITIONAL INSULIN OR GLP-1 RECEPTOR AGONIST: CROSSROADS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. vol 23. issue 11. 2018-02-14. PMID:29190136. |
nutritional insulin or glp-1 receptor agonist: crossroads in the treatment of type 2 diabetes mellitus. |
2018-02-14 |
2023-08-13 |
Not clear |
| Fiona McCartney, John P Gleeson, David J Brayde. Safety concerns over the use of intestinal permeation enhancers: A mini-review. Tissue barriers. vol 4. issue 2. 2018-02-01. PMID:27358756. |
intestinal permeation enhancers (pes) are key components in ∼12 oral peptide formulations in clinical trials for a range of molecules, primarily insulin and glucagon-like-peptide 1 (glp-1) analogs. |
2018-02-01 |
2023-08-13 |
Not clear |
| Michael A Nauck, Juris J Meie. The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions. The lancet. Diabetes & endocrinology. vol 4. issue 6. 2018-01-30. PMID:26876794. |
incretin-based drugs, including glp-1 receptor agonists and dipeptidyl peptidase 4 (dpp-4) inhibitors, stimulate glp-1 receptors and thus augment insulin secretion in response to both oral and intravenous glucose stimulation, thereby abolishing any potential difference in the responses to these stimuli. |
2018-01-30 |
2023-08-13 |
Not clear |
| Lili Tian, Tianru Ji. The incretin hormone GLP-1 and mechanisms underlying its secretion. Journal of diabetes. vol 8. issue 6. 2018-01-30. PMID:27287542. |
in addition to serving as an incretin in mediating the effect of meal consumption on insulin secretion, glp-1 exerts other functions in pancreatic islets, including regulation of β-cell proliferation and protection of β-cells against metabolic stresses. |
2018-01-30 |
2023-08-13 |
Not clear |
| Rikke M Røge, Jonatan I Bagger, Oskar Alskär, Niels R Kristensen, Søren Klim, Jens J Holst, Steen H Ingwersen, Mats O Karlsson, Filip K Knop, Tina Vilsbøll, Maria C Kjellsso. Mathematical Modelling of Glucose-Dependent Insulinotropic Polypeptide and Glucagon-like Peptide-1 following Ingestion of Glucose. Basic & clinical pharmacology & toxicology. vol 121. issue 4. 2018-01-30. PMID:28374974. |
the incretin hormones, glucose-dependent insulinotropic polypeptide (gip) and glucagon-like peptide-1 (glp-1), play an important role in glucose homeostasis by potentiating glucose-induced insulin secretion. |
2018-01-30 |
2023-08-13 |
human |
| Cheryl L Rock, Shirley W Flatt, Hava-Shoshana Barkai, Bilge Pakiz, Dennis D Heat. A walnut-containing meal had similar effects on early satiety, CCK, and PYY, but attenuated the postprandial GLP-1 and insulin response compared to a nut-free control meal. Appetite. vol 117. 2018-01-29. PMID:28610906. |
a walnut-containing meal had similar effects on early satiety, cck, and pyy, but attenuated the postprandial glp-1 and insulin response compared to a nut-free control meal. |
2018-01-29 |
2023-08-13 |
Not clear |